Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 276

1.

CD133+CD44+ population efficiently enriches colon cancer initiating cells.

Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, Kamohara Y, Inoue H, Mori M.

Ann Surg Oncol. 2008 Oct;15(10):2927-33. doi: 10.1245/s10434-008-0074-0. Epub 2008 Jul 29.

PMID:
18663533
2.

CD49f-positive cell population efficiently enriches colon cancer-initiating cells.

Haraguchi N, Ishii H, Mimori K, Ohta K, Uemura M, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Doki Y, Mori M.

Int J Oncol. 2013 Aug;43(2):425-30. doi: 10.3892/ijo.2013.1955. Epub 2013 May 24.

PMID:
23708747
3.

Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.

Chen KL, Pan F, Jiang H, Chen JF, Pei L, Xie FW, Liang HJ.

Clin Exp Metastasis. 2011 Dec;28(8):751-63. doi: 10.1007/s10585-011-9407-7. Epub 2011 Jul 13.

PMID:
21750907
4.

CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.

Rocco A, Liguori E, Pirozzi G, Tirino V, Compare D, Franco R, Tatangelo F, Palaia R, D'Armiento FP, Pollastrone G, Affuso A, Bottazzi EC, Masone S, Persico G, Nardone G.

J Cell Physiol. 2012 Jun;227(6):2686-93. doi: 10.1002/jcp.23013.

PMID:
21898409
5.

Cultivation and identification of colon cancer stem cell-derived spheres from the Colo205 cell line.

Li YF, Xiao B, Tu SF, Wang YY, Zhang XL.

Braz J Med Biol Res. 2012 Mar;45(3):197-204. Epub 2012 Feb 9.

6.

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.

Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.

PLoS One. 2011;6(6):e20636. doi: 10.1371/journal.pone.0020636. Epub 2011 Jun 13.

7.

Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.

Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI.

Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):19-29.

8.

The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.

Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G.

Eur J Cardiothorac Surg. 2009 Sep;36(3):446-53. doi: 10.1016/j.ejcts.2009.03.063. Epub 2009 May 22.

PMID:
19464919
9.

Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection.

Sgambato A, Puglisi MA, Errico F, Rafanelli F, Boninsegna A, Rettino A, Genovese G, Coco C, Gasbarrini A, Cittadini A.

J Cell Physiol. 2010 Jul;224(1):234-41. doi: 10.1002/jcp.22124.

PMID:
20333645
10.

FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.

Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim HK, Bae KB, Park YH, Kim SU, Kim JM, Kim N, Ko KS, Rhee BD, Han J.

Gastroenterology. 2015 Oct;149(4):1006-16.e9. doi: 10.1053/j.gastro.2015.06.007. Epub 2015 Jun 17.

PMID:
26091938
11.

Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?

Wei C, Guomin W, Yujun L, Ruizhe Q.

Cancer Biol Ther. 2007 May;6(5):763-8. Epub 2007 Feb 8.

PMID:
17592251
12.

Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties.

Navarro-Alvarez N, Kondo E, Kawamoto H, Hassan W, Yuasa T, Kubota Y, Seita M, Nakahara H, Hayashi T, Nishikawa Y, Hassan RA, Javed SM, Noguchi H, Matsumoto S, Nakaji S, Tanaka N, Kobayashi N, Soto-Gutierrez A.

Cell Transplant. 2010;19(6):865-77. doi: 10.3727/096368910X508997. Epub 2010 Jun 29.

13.

Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells.

Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M.

PLoS One. 2014 Apr 23;9(4):e94621. doi: 10.1371/journal.pone.0094621. eCollection 2014.

14.

Role of CD44(high)/CD133(high) HCT-116 cells in the tumorigenesis of colon cancer.

Zhou JY, Chen M, Ma L, Wang X, Chen YG, Liu SL.

Oncotarget. 2016 Feb 16;7(7):7657-66. doi: 10.18632/oncotarget.7084.

15.

Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis.

Bellizzi A, Sebastian S, Ceglia P, Centonze M, Divella R, Manzillo EF, Azzariti A, Silvestris N, Montemurro S, Caliandro C, De Luca R, Cicero G, Rizzo S, Russo A, Quaranta M, Simone G, Paradiso A.

J Cell Physiol. 2013 Feb;228(2):408-15. doi: 10.1002/jcp.24145.

PMID:
22740326
16.

STAT3 is necessary for proliferation and survival in colon cancer-initiating cells.

Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C, Lin J.

Cancer Res. 2011 Dec 1;71(23):7226-37. doi: 10.1158/0008-5472.CAN-10-4660. Epub 2011 Sep 7.

17.

Expression of CD133 correlates with differentiation of human colon cancer cells.

Feng HL, Liu YQ, Yang LJ, Bian XC, Yang ZL, Gu B, Zhang H, Wang CJ, Su XL, Zhao XM.

Cancer Biol Ther. 2010 Feb;9(3):216-23. Epub 2010 Feb 16.

PMID:
20023382
18.

CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.

Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, Li X, He Z, Gong W, Qin R.

Cancer Biol Ther. 2010 Dec 1;10(11):1182-90. Epub 2010 Dec 1.

PMID:
20948317
19.

CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.

Muraro MG, Mele V, Däster S, Han J, Heberer M, Cesare Spagnoli G, Iezzi G.

Stem Cells Transl Med. 2012 Aug;1(8):592-603. doi: 10.5966/sctm.2012-0003. Epub 2012 Aug 6.

20.

CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.

Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S.

J Clin Invest. 2008 Jun;118(6):2111-20. doi: 10.1172/JCI34401.

Supplemental Content

Support Center